Edition:
United States

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

12.04USD
12:06pm EST
Change (% chg)

$0.09 (+0.75%)
Prev Close
$11.95
Open
$12.07
Day's High
$12.28
Day's Low
$11.90
Volume
34,727
Avg. Vol
81,038
52-wk High
$12.28
52-wk Low
$2.52

Select another date:

Wed, Jan 3 2018

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

BRIEF-RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals

* RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING

BRIEF-Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals

* BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING

BRIEF-Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

* DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering

* DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING Source text : (http://bit.ly/2o22t2b) Further company coverage:

BRIEF-Dicerna announces proposed public offering of common stock

* DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC

* DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA

BRIEF-Dicerna Pharmaceuticals Q3 loss per share ‍$0.92

* Q3 2017 loss per share ‍$0.92 Source text for Eikon: Further company coverage:

BRIEF-Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis

* Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH)

Alnylam loses bid to toss Dicerna counterclaims in trade secrets case

Drugmaker Alnylam Pharmaceuticals has lost its bid to dismiss counterclaims that rival Dicerna Pharmaceuticals asserted in response to a trade secrets lawsuit brought by Alnylam two years ago.

Select another date: